Pathwork Diagnostics, a US-based developer of genomics-based diagnostics in oncology, has entered into a collaboration agreement with Kindstar Global to provide its FDA cleared in vitro diagnostic (IVD) kit version of the Pathwork Tissue of Origin Test.
The collaboration, which Pathwork claims to be the first IVD kit agreement, will allow Kindstar to offer a new test for cancer diagnosis to Chinese hospitals.
Pathwork Diagnostics president and CEO Lee McCracken said the Pathwork Tissue of Origin test determines site of origin for lesions that are poorly differentiated or show staining and morphology patterns that are inconsistent with clinical expectations.
"We are pleased to partner with Kindstar and provide the rapidly expanding Chinese market with access to our innovative test," McCracken added.
Kindstar Global founder and CEO Shiang Huang said, "Having access to this test will allow us to expand the current testing services we offer Chinese physicians and position our business as the leading diagnostic company in the fastest growing market in the world."
With laboratory facilities in Beijing, Shanghai and Wuhan, Kindstar provides specialty clinical testing services in China and offers esoteric diagnostic testing and laboratory testing services to Chinese hospitals, including tertiary care hospitals.
